Is a sessile serrated lesion considered an adenoma polyp?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, a sessile serrated lesion is NOT an adenoma polyp—it is a distinct type of serrated polyp with its own molecular pathway to colorectal cancer.

Sessile serrated lesions (SSLs) represent a separate category of premalignant colorectal polyps that differ fundamentally from conventional adenomas in their histology, molecular characteristics, and pathway to cancer. While both can lead to colorectal cancer, they do so through entirely different mechanisms 1.

Key Distinctions Between SSLs and Adenomas

Molecular Pathways

  • SSLs progress via the "serrated neoplasia pathway" characterized by:

    • BRAF mutations (rather than APC mutations seen in adenomas)
    • CpG island methylator phenotype (CIMP)
    • Potential for microsatellite instability (MSI-H)
    • Epigenetic silencing of tumor suppressor genes 1
  • Conventional adenomas progress via the "adenoma-carcinoma sequence" with:

    • Sequential accumulation of genetic mutations
    • Chromosomal instability
    • Microsatellite stable (MSS) tumors 1

Histologic Features

SSLs show characteristic saw-toothed crypt architecture with abnormal proliferation patterns, asymmetrical crypt architecture, crypt branching, and basal crypt dilatations—features distinct from the tubular or villous architecture of conventional adenomas 2, 3.

Clinical Significance

SSLs account for 15-30% of all colorectal cancers and contribute disproportionately to interval cancers (cancers detected between screening examinations) 1, 4. This is partly due to their:

  • Difficulty in endoscopic detection
  • Proximal (right-sided) predominance
  • Flat morphology with mucus caps
  • Potential for rapid progression when dysplasia develops

Management Implications

The distinction matters clinically because:

Surveillance Intervals Differ

  • SSLs ≥10mm or with dysplasia: 3-year surveillance colonoscopy 1
  • SSLs <10mm without dysplasia: No clear indication for surveillance unless meeting serrated polyposis syndrome criteria 1
  • These recommendations differ from adenoma surveillance protocols

Resection Considerations

  • SSLs require complete resection with clear margins
  • Piecemeal resection of SSLs ≥20mm warrants site check at 2-6 months 1
  • Cold snare polypectomy may be appropriate for selected non-dysplastic SSLs with defined margins 4

Common Pitfall

The critical error is classifying all serrated polyps as "hyperplastic" or lumping SSLs with adenomas. SSLs were historically under-recognized and misclassified as benign hyperplastic polyps 5, 6. Recognition of their distinct premalignant potential is essential for appropriate management and cancer prevention.

Traditional Serrated Adenomas

Note that traditional serrated adenomas (TSAs) are yet another distinct entity with different molecular features (KRAS mutations, variable CIMP) and should also be managed as high-risk lesions requiring 3-year surveillance 1.

References

Research

Endoscopic Assessment and Management of Colorectal Serrated Lesions: Current Comparative Practice, Challenges, and Future Directions.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2026

Research

Sessile serrated adenoma: from identification to resection.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015

Research

Sessile serrated adenoma: a brief history and current status.

Critical reviews in oncogenesis, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.